- Home
- VLGEA vs FLGT Comparison
VLGEA vs FLGT Comparison
Compare VLGEA & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VLGEA | FLGT |
|---|---|---|
| Founded | 1937 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 612.5M | 511.2M |
| IPO Year | 1994 | 2016 |
Fundamental Metrics
Financial Performance| Metric | VLGEA | FLGT |
|---|---|---|
| Price | $42.51 | $20.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $28.33 |
| AVG Volume (30 Days) | 48.9K | ★ 273.9K |
| Earning Date | 06-02-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,612,015,000.00 | $18,730,000.00 |
| Revenue This Year | N/A | $10.09 |
| Revenue Next Year | N/A | $12.18 |
| P/E Ratio | $10.31 | ★ N/A |
| Revenue Growth | ★ 0.46 | N/A |
| 52 Week Low | $30.08 | $13.46 |
| 52 Week High | $48.21 | $31.04 |
Technical Indicators
Market Signals| Indicator | VLGEA | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 52.40 | 65.84 |
| Support Level | $41.72 | $13.91 |
| Resistance Level | $43.30 | $23.70 |
| Average True Range (ATR) | 1.16 | 0.66 |
| MACD | 0.20 | 0.13 |
| Stochastic Oscillator | 74.16 | 78.23 |
Price Performance
Historical ComparisonAbout VLGEA Village Super Market Inc.
Village Super Market Inc operates a chain of ShopRite supermarkets, a few of which are in northern New Jersey, southern New Jersey, Maryland, and in northeastern Pennsylvania. The company is a member of Wakefern Food Corporation (Wakefern), a retailer-owned food cooperative and owner of the ShopRite name. It consists of one operating segment, the retail sale of food and nonfood products.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.